Showing results (321-330 of 777) with videos related to
Sort By:
Pageof 78
Immunotherapy|September 16, 2015
Targeting B-cell maturation antigen in multiple myelomaYu-Tzu Tai, Kenneth C AndersonHematology. American Society of Hematology. Education Program|December 4, 2018
Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologistTanya M Wildes, Kenneth C AndersonCritical Reviews in Oncology/Hematology|May 15, 2002
What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?Richard J Benjamin, Kenneth C AndersonBlood Cancer Discovery|October 18, 2021
Blood Cancer Discovery Turns OneRiccardo Dalla-Favera, Kenneth C AndersonExpert Opinion on Biological Therapy|July 7, 2019
B cell maturation antigen (BCMA)-based immunotherapy for multiple myelomaYu-Tzu Tai, Kenneth C AndersonBlood|August 24, 2007
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsSonia Vallet, Noopur Raje, Kenji Ishitsuka, et al.Mediterranean Journal of Hematology and Infectious Diseases|March 19, 2011
The treatment of multiple myeloma patients not eligible for asctPaul Richardson, Jacob Laubach, Anuj Mahindra, et al.Blood|January 21, 2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaLoredana Santo, Teru Hideshima, Andrew L Kung, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironmentAlissa Huston, Xavier Leleu, Xiaoying Jia, et al.Nature Communications|January 6, 2016
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survivalHiroto Ohguchi, Teru Hideshima, Manoj K Bhasin, et al.Pageof 78